Crescita Therapeutics Inc. is a drug development company. The Company owns products for treating medical conditions in dermatology and pain. It owns various drug delivery platforms, which include Durapeel and Foam technology to support the development of patented formulations that can deliver actives into or through the skin. It operates two business units: the Topical Products and Technology (TPT) Group and the Immunology Group. The TPT Group product, Pliaglis and other products are focused on dermatology and pain. Its product Flexicaine is in Phase II clinical stage and has therapeutic area in Tick-borne disease. Its product Ibuprofen Foam is in pre-clinical stage and has therapeutic area in Acute Pain. Its product Terbinafine is in pre-clinical stage and has therapeutic area in Onychomycosis. Its product Mical 1 is in pre-clinical stage and has therapeutic area in Psoriasis. Its product Mical 2 is in pre-clinical stage and has therapeutic area in Dermatological skin treatment.